罗迪克桑的链传递动力学® A1 RAFT/MADIX代理的链传递动力学
Mathias Destarac1, Aymeric Guinaudeau1,2, Stéphane Mazières1
1Laboratoire SOFTMAT, CNRS UMR 5623, University of Toulouse, University Toulouse III-Paul Sabatier, 118 Route de Narbonne, 31062 Toulouse Cedex 9, France.
Molecules (Basel, Switzerland)
|January 8, 2025
概括
作为RAFT/MADIX剂的Rhodixan® A1使得可以在工业规模生产区块共聚合物添加剂. 它在各种单体中实现了预先确定的分子量,转移系数因单体类型而异.
科学领域:
- 聚合物化学 聚合物化学
- 材料科学 材料科学 材料科学
背景情况:
- 块共聚合物添加剂的工业规模生产对于水性配方至关重要.
- 包括RAFT/MADIX在内的可逆失活激进聚合 (RDRP) 技术可以控制聚合物架构.
- 罗迪克桑® A1 (O-乙烯-S-1-甲氧化碳乙烯-乙烯) 乙二碳酸盐) 是一个关键的RAFT/MADIX药物.
研究的目的:
- 评估Rhodixan® A1在生产块共聚合物添加剂中的有效性.
- 为了确定Rhodixan® A1与各种单体类的链转移系数.
- 评估对聚合物分子质量和分散性的控制.
主要方法:
- 使用了25种不同的 styrenic,acrylate 和 acrylamide 单体.
- 通过实验确定了链转移系数 (Ctr) 和链际转移系数 (Ctr,PnXA1).
- 在高单体转换下分析了聚合物分子量和分散性.
主要成果:
- 对Rhodixan® A1的连锁转移系数较低,范围为0.6至3.8.
- 转移系数按照下面的顺序进行: styrenics < 烯酸盐 < 烯胺.
- 预先确定分子重量的聚合物得到了分散度与Ctr,PnXA1相成比例.
结论:
- Rhodixan® A1 促进了具有受控分子量的块共聚合物的工业规模合成.
- 使用Rhodixan® A1的RAFT/MADIX技术可用于从具有不同反应性的单体中制造复杂的共聚物.
- 这种药物对结合和未结合的单体都有效,扩大了其适用性.
相关概念视频
Radical Chain-Growth Polymerization: Overview
2.4K
Chain-growth or addition polymerization is successive addition reactions of monomers with a polymer chain. In radical chain-growth polymerization, the reaction proceeds via a free-radical intermediate. The free radical is formed from radical initiators, which spontaneously generate free radicals by homolytic fission. Organic peroxides (such as dibenzoyl peroxide, as shown in Figure 1) or azo compounds are popular radical initiators. A low concentration ratio of radical initiator to monomer is...
2.4K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K


